%0 Journal Article
%T 小檗碱通过调节肠道菌群治疗2型糖尿病<br>Berberine Treats Type 2 Diabetes by Regulating Gutmicrobiota
%A 白雪
%A 卿岚
%A 朱路阳
%A 王婷
%A 赵媛
%J Advances in Clinical Medicine
%P 922-927
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.1472096
%X 2型糖尿病(T2DM)及其并发症是一种严重威胁人们生活质量的公共卫生问题。肠道菌群的调节在T2DM的治疗已得到广泛认可，已有证据表明肠道菌群对葡萄糖代谢有影响，通过调节肠道菌群治疗糖尿病具有重要临床应用前景。小檗碱(BBR)是黄连的主要成分，通过调节肠道菌群可降糖、降脂，以及减重和抗炎，被认为是治疗T2DM的潜在药物之一。<br />
Type 2 diabetes mellitus (T2DM) and its complications are major public health problems that seriously affect the quality of human life. The regulation of gut microbiota has been widely recognized in T2DM treatment. There have been evidences that gut microbiota has an impact on glucose metabolism, and the regulation of gut microbiota in diabetes treatment has an important clinical application prospect. Berberine (BBR), the main component of Coptischinensis, is considered as one of the potential strategies in T2DM treatment by regulating gut microbiota, which can reduce blood sugar, blood lipid, weight loss and anti-inflammatory.
%K 小檗碱(BBR)，2型糖尿病(T2DM)，肠道菌群<br>Berberine (BBR)
%K Type 2 Diabetes Mellitus (T2DM)
%K Gut Microbiota
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=91909